As of 2024, the AAOS Clinical Practice Guidelines (CPG) updated the evidence rating for bioinductive and bioconductive augmentation in rotator cuff repairs to ”Moderate” or “Strong.” This reflects an industry shift from mechanical fixation to biological integration. 

Data from the 2026 AAOS Annual Meeting indicates that biomimetic scaffolds, which replicate the extracellular matrix (ECM) to recruit progenitor cells, yield a 65% relative reduction in re-tear rates for full-thickness tears. Clinical evidence at two-year follow-up confirms improved tissue quality and patient-reported outcomes compared to standard repair. 

While Smith+Nephew’s REGENETEN (bovine collagen) remains the high-volume market leader, clinicians are increasingly adopting synthetic electrospun polymer scaffolds  (e.g., Rotium and Biowick) and biosynthetic hybrid scaffolds  (e.g., BioBrace, Tapestry). These alternatives address animal-protein sensitivities and utilize nanofiber architecture to optimize the bone-to-tendon interface. 

The Electrospinning Company is a leader in the development and manufacture of advanced materials for surgical augmentation.  

With a ten-year track record of supplying synthetic electrospun components for FDA-approved sports medicine products in the US market (see case study).

Our Symatix® portfolio offers a biosynthetic alternative to traditional grafts, integrating synthetic polymer scaffolds with collagen or hyaluronic acid. This approach provides the mechanical integrity of a synthetic matrix alongside the biological benefits of natural polymers. Critically, Symatix® materials are designed for reproducibility and cost-competitive scaling, offering a high-performance substitute for bovine-derived grafts in the orthopaedic sector. Read more about Symatix® here.